** Shares of Antengene Corp 6996.HK rise 5.6% to HK$5.84
** Stock at highest level since Feb 2023, set for sixth consecutive session of gains
** Innovative oncology medicines-focused clinical-stage biopharmaceutical group says its Xpovio approved in China for second-line treatment of multiple myeloma
** Hang Seng Biotech Index .HSHKBIO rises 2.6%, while benchmark Hang Seng Index .HSI falls 1.1%
** YTD, stock up 783%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。